Form 4: Crinetics Pharmaceuticals Director Reports Stock Transaction
Insider Transaction (Form 4)
Stephanie Okey, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.
Summary
- Disposition to the issuer: disposed of 6,400 Common Stock at $85.00 ($544,000) on September 1, 2026; holds 5,925 after (Direct).
- Disposition to the issuer: disposed of 5,925 Common Stock at $85.00 ($503,625) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 25,000 Stock Option (Right to Buy) at $60.85 ($1,521,250) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 12,500 Stock Option (Right to Buy) at $61.77 ($772,125) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 17,500 Stock Option (Right to Buy) at $64.77 ($1,133,475) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 17,500 Stock Option (Right to Buy) at $64.68 ($1,131,900) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 12,500 Stock Option (Right to Buy) at $40.29 ($503,625) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 10,350 Stock Option (Right to Buy) at $52.67 ($545,134) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 9,730 Stock Option (Right to Buy) at $49.13 ($478,035) on September 1, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Stephanie Okey — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Disposition to the issuer | Common Stock | 6,400 | $85 | $544.0K | 5,925 |
| 2026-09-01 | Disposition to the issuer | Common Stock | 5,925 | $85 | $503.6K | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 25,000 | $61 | $1.5M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 12,500 | $62 | $772.1K | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 17,500 | $65 | $1.1M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 17,500 | $65 | $1.1M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 12,500 | $40 | $503.6K | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 10,350 | $53 | $545.1K | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 9,730 | $49 | $478.0K | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Disposition to the issuer (6,400 shares) |
| 2026-09-01 | Disposition to the issuer (5,925 shares) |
| 2026-09-01 | Disposition to the issuer (25,000 shares) |
| 2026-09-01 | Disposition to the issuer (12,500 shares) |
| 2026-09-01 | Disposition to the issuer (17,500 shares) |
| 2026-09-01 | Disposition to the issuer (17,500 shares) |
| 2026-09-01 | Disposition to the issuer (12,500 shares) |
| 2026-09-01 | Disposition to the issuer (10,350 shares) |
| 2026-09-01 | Disposition to the issuer (9,730 shares) |
Keywords
insider transaction, Form 4, CRNX, Crinetics Pharmaceuticals, Inc., neutral, Stephanie Okey
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.